Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of XTX202 monotherapy in advanced solid tumors
MOH_2023-05-18_012650Phase 2Completed
- Sponsor
- Xilio Development
- Start
- Apr 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XTX202 in Nonhematologic neoplasms, renal cell carcinoma (RCC) and melanoma, sponsored by Xilio Development. Started Apr 2023; status: completed.
02
Drugs
XTX202
03
Conditions
Nonhematologic neoplasmsrenal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on MOH_2023-05-18_012650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-18_012650.